Alzheimer’s Breakthrough + Biosimilar Landscape
Sue Peschin, President and CEO of the Alliance for Aging Research, says Medicare coverage for Alzheimer’s drugs is something millions across the country truly care about as an election year nears; the Biden Administration is taking action to limit...
Sue Peschin, President and CEO of the Alliance for Aging Research, says Medicare coverage for Alzheimer’s drugs is something millions across the country truly care about as an election year nears; the Biden Administration is taking action to limit insurance “junk fees” for patients; Patients Rising Now will host a Hill briefing on Accelerated Approval on Monday, July 24th; and Sarah Ikenberry, Senior Communication Advisor for the Office of Therapeutic Biologics and Biosimilars at the FDA, discusses the biosimilar landscape as new Humira biosimilars hit the market.
Alliance for Aging Research Poll: Huge Majorities Want Medicare to Cover Cost of Alzheimer’s Drugs
Register: The Value of Accelerated Approval for Patient Access & Future Medical Advances Event
Real Clear Markets OpEd: Promising New Alzheimer's Drug Calls for CMS to Rethink Access Restrictions
Listen On
